Key Points
- CEO Clay Siegall purchased 46,511 shares at $21.50 each on Dec. 18 for a total of $999,986.50, raising his stake to 853,247 shares (a 5.77% increase), as disclosed in an SEC Form 4 filing.
- Wall Street sentiment has turned bullish—multiple firms recently raised price targets (Evercore to $40, Truist $36) and the consensus is an average target of $30.09 with 10 Buy ratings versus one Sell.
- Immunome is a clinical-stage biotech (Phase 3 asset AL102) with a $1.83 billion market cap, but it reported negative EPS (-$0.65) and a very large negative net margin, and its 1‑year trading range is $5.15–$25.30.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay Siegall acquired 46,511 shares of the business's stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $21.50 per share, with a total value of $999,986.50. Following the acquisition, the chief executive officer owned 853,247 shares in the company, valued at $18,344,810.50. The trade was a 5.77% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Immunome Price Performance
Shares of Immunome stock opened at $19.95 on Friday. The stock's 50 day simple moving average is $17.53 and its 200-day simple moving average is $12.60. The stock has a market cap of $1.83 billion, a P/E ratio of -6.76 and a beta of 2.17. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $25.30.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently commented on IMNM shares. Evercore ISI lifted their price target on Immunome from $18.00 to $40.00 and gave the stock an "outperform" rating in a report on Tuesday. Lake Street Capital lifted their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday. Stephens boosted their target price on shares of Immunome from $25.00 to $33.00 and gave the company an "overweight" rating in a report on Monday, November 17th. Truist Financial initiated coverage on shares of Immunome in a research note on Monday, December 1st. They issued a "buy" rating and a $36.00 price target for the company. Finally, Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a report on Saturday, November 22nd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $30.09.
View Our Latest Report on IMNM
Hedge Funds Weigh In On Immunome
A number of hedge funds have recently made changes to their positions in the stock. Assetmark Inc. acquired a new stake in Immunome in the 3rd quarter valued at approximately $39,000. BIT Capital GmbH acquired a new position in Immunome during the third quarter worth $69,000. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Immunome in the third quarter valued at $76,000. Finally, Tower Research Capital LLC TRC lifted its stake in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after acquiring an additional 3,802 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
